Cytoplasmic rods and rings autoantibodies developed during pegylated interferon and ribavirin therapy in patients with chronic hepatitis C

Antiviral Therapy

Volumn 17, Issue 5, 2012, Pages 805-811

  Covini, Giovanni ^a   Carcamo, Wendy C ^b   Bredi, Elena ^a   Von Mühlen, Carlos A ^c   Colombo, Massimo ^d   Chan, Edward K L ^b  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF FLORIDA   (United States)

^c Rheuma Clinic for Rheumatic Diseases   (Brazil)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; LIVER KIDNEY MICROSOMAL ANTIBODY; PEGINTERFERON ALPHA2A; RIBAVIRIN; RODS AND RINGS ANTIBODY; SMOOTH MUSCLE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPLASM; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RAT; RELAPSE; RETROSPECTIVE STUDY;

ADULT; ANIMALS; ANTIVIRAL AGENTS; AUTOANTIBODIES; CELL LINE; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; ORGANELLES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84855258752     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1993     Document Type: Article

References (42)

1. Abuaf N, Lunel F, Giral P, et al. Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol 1993; 18:359-364.
2. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997; 26:561-566.
3. Clifford BD, Donahue D, Smith L, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology 1995; 21:613-619.
4. Covini G, von Muhlen CA, Pacchetti S, et al. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol 1997; 26:1255-1265.
5. Fried MW, Draguesku JO, Shindo M, et al. Clinical and serological differentiation of autoimmune and hepatitis C virus-related chronic hepatitis. Dig Dis Sci 1993; 38:631-636.
6. Lenzi M, Bellentani S, Saccoccio G, et al. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 1999; 45:435-441.
7. Lenzi M, Johnson PJ, McFarlane IG, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 1991; 338:277-280.
8. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132:587-593.
9. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993; 18:253-257.
10. Williams MJ, Lawson A, Neal KR, et al. Autoantibodies in chronic hepatitis C virus infection and their association with disease profile. J Viral Hepat 2009; 16:325-331.
11. Maecker HT, Do MS, Levy S. CD81 on B cells promotes interleukin 4 secretion and antibody production during T helper type 2 immune responses. Proc Natl Acad Sci U S A 1998; 95:2458-2462.
12. Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998; 282:938-941.
13. Gregorio GV, Choudhuri K, Ma Y, et al. Mimicry between the hepatitis C virus polyprotein and antigenic targets of nuclear and smooth muscle antibodies in chronic hepatitis C virus infection. Clin Exp Immunol 2003; 133:404-413.
14. Kammer AR, van der Burg SH, Grabscheid B, et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 1999; 190:169-176.
15. Sutti S, Vidali M, Mombello C, et al. Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic hepatitis C: possible role for molecular mimicry. J Hepatol 2010; 53:431-438.
16. Yamamoto AM, Cresteil D, Boniface O, et al. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993; 23:1105-1111.
17. Dalekos GN, Wedemeyer H, Obermayer-Straub P, et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol 1999; 30:366-375.
18. Fabbri C, Jaboli MF, Giovanelli S, et al. Gastric autoimmune disorders in patients with chronic hepatitis C before, during and after interferon-alpha therapy. World J Gastroenterol 2003; 9:1487-1490.
19. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet 1992; 340:548.
20. Fabris P, Betterle C, Greggio NA, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28:514-517.
21. García-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108:1770-1777.
22. Imagawa A, Itoh N, Hanafusa T, et al. Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis. Diabetologia 1996; 39:126.
23. Papo T, Marcellin P, Bernuau J, et al. Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med 1992; 116:51-53.
24. Shindo M, Di Bisceglie AM, Hoofnagle JH. Acute exacerbation of liver disease during interferon alfa therapy for chronic hepatitis C. Gastroenterology 1992; 102:1406-1408.
25. Todros L, Saracco G, Durazzo M, et al. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes. Hepatology 1995; 22:1374-1378.
26. Wesche B, Jaeckel E, Trautwein C, et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C. Gut 2001; 48:378-383.
27. Baron S, Tyring SK, Fleischmann WR, Jr., et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991; 266:1375-1383.
28. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
29. Kogure T, Ueno Y, Fukushima K, et al. Fulminant hepatic failure in a case of autoimmune hepatitis in hepatitis C during peg-interferon-alpha 2b plus ribavirin treatment. World J Gastroenterol 2007; 13:4394-4397.
30. Narciso-Schiavon JL, Freire FC, Suarez MM, et al. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon? Eur J Gastroenterol Hepatol 2009; 21:440-446.
31. Ferri S, Muratori L, Quarneti C, et al. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol 2009; 50:1093-1101.
32. Gatselis NK, Georgiadou SP, Koukoulis GK, et al. Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C. Aliment Pharmacol Ther 2006; 24:1563-1573.
33. Wasmuth HE, Stolte C, Geier A, et al. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004; 4:4.
34. Yee LJ, Kelleher P, Goldin RD, et al. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. J Viral Hepat 2004; 11:459-464.
35. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130:231-264.
36. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31:929-938.
37. Jakymiw A, Pauley KM, Li S, et al. The role of GW/P-bodies in RNA processing and silencing. J Cell Sci 2007; 120:1317-1323.
38. Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol 1984; 55:561-570.
39. Matsuda J, Saitoh N, Gotoh M, et al. High prevalence of anti-phospholipid antibodies and anti-thyroglobulin antibody in patients with hepatitis C virus infection treated with interferon-alpha. Am J Gastroenterol 1995; 90:1138-1141.
40. Stroffolini T, Colloredo G, Gaeta GB, et al. Does an 'autoimmune' profile affect the clinical profile of chronic hepatitis C? An Italian multicentre survey. J Viral Hepat 2004; 11:257-262.
41. Tan EM. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989; 44:93-151.
42. Tan EM. Autoantibodies in pathology and cell biology. Cell 1991; 67:841-842.